These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 29718739)

  • 1. Emerging therapeutic targets for treatment of leishmaniasis.
    Sundar S; Singh B
    Expert Opin Ther Targets; 2018 Jun; 22(6):467-486. PubMed ID: 29718739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery.
    Chandra S; Ruhela D; Deb A; Vishwakarma RA
    Expert Opin Ther Targets; 2010 Jul; 14(7):739-57. PubMed ID: 20536412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assay development in leishmaniasis drug discovery: a comprehensive review.
    Zulfiqar B; Avery VM
    Expert Opin Drug Discov; 2022 Feb; 17(2):151-166. PubMed ID: 34818139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease inhibitors in potential drug development for Leishmaniasis.
    Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
    Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmaniasis drug discovery: recent progress and challenges in assay development.
    Zulfiqar B; Shelper TB; Avery VM
    Drug Discov Today; 2017 Oct; 22(10):1516-1531. PubMed ID: 28647378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Need for sustainable approaches in antileishmanial drug discovery.
    Hendrickx S; Caljon G; Maes L
    Parasitol Res; 2019 Oct; 118(10):2743-2752. PubMed ID: 31473855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.
    Alcântara LM; Ferreira TCS; Gadelha FR; Miguel DC
    Int J Parasitol Drugs Drug Resist; 2018 Dec; 8(3):430-439. PubMed ID: 30293058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic targets and the role of technology in developing novel antileishmanial drugs.
    Rajasekaran R; Chen YP
    Drug Discov Today; 2015 Aug; 20(8):958-68. PubMed ID: 25936844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising therapeutic targets for antileishmanial drugs.
    Werbovetz KA
    Expert Opin Ther Targets; 2002 Aug; 6(4):407-22. PubMed ID: 12223057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational approaches for drug designing against leishmaniasis.
    Shukla AK; Singh BK; Patra S; Dubey VK
    Appl Biochem Biotechnol; 2010 Apr; 160(8):2208-18. PubMed ID: 19756413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.
    Sundar S; Agrawal N; Singh B
    Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):595-612. PubMed ID: 31174439
    [No Abstract]   [Full Text] [Related]  

  • 12. Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: a review.
    Cruz AK; de Toledo JS; Falade M; Terrão MC; Kamchonwongpaisan S; Kyle DE; Uthaipibull C
    Curr Drug Targets; 2009 Mar; 10(3):178-92. PubMed ID: 19275555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance in leishmaniasis.
    Croft SL; Sundar S; Fairlamb AH
    Clin Microbiol Rev; 2006 Jan; 19(1):111-26. PubMed ID: 16418526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of leishmaniasis: present challenges.
    Uliana SRB; Trinconi CT; Coelho AC
    Parasitology; 2018 Apr; 145(4):464-480. PubMed ID: 28103966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of leishmaniasis: a review and assessment of recent research.
    Elmahallawy EK; Agil A
    Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery.
    das Neves GM; Kagami LP; Gonçalves IL; Eifler-Lima VL
    Future Med Chem; 2019 Aug; 11(16):2107-2130. PubMed ID: 31370699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases.
    Kourbeli V; Chontzopoulou E; Moschovou K; Pavlos D; Mavromoustakos T; Papanastasiou IP
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
    Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
    Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of leishmaniasis.
    Balaña-Fouce R; Reguera RM; Cubría JC; Ordóñez D
    Gen Pharmacol; 1998 Apr; 30(4):435-43. PubMed ID: 9580315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays.
    Berry SL; Hameed H; Thomason A; Maciej-Hulme ML; Saif Abou-Akkada S; Horrocks P; Price HP
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006639. PubMed ID: 30001317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.